Injecting automation early fuels risk
To avoid risk when developing CGTs you must remove process complexities before implementing automation, says ScaleReady. Digital processes and artificial intelligence (AI) are being explored and adopted in various ways to advance and improve the manufacturing processes for cell and gene therapies (CGTs). Furthermore, automation has long been deemed necessary in the industry to avoid…